Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

L'Imperio, V; Wulczyn, E; Plass, M; Müller, H; Tamini, N; Gianotti, L; Zucchini, N; Reihs, R; Corrado, GS; Webster, DR; Peng, LH; Chen, PC; Lavitrano, M; Liu, Y; Steiner, DF; Zatloukal, K; Pagni, F.
Pathologist Validation of a Machine Learning-Derived Feature for Colon Cancer Risk Stratification.
JAMA Netw Open. 2023; 6(3): e2254891 Doi: 10.1001/jamanetworkopen.2022.54891 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Plass Markus
Co-Autor*innen der Med Uni Graz
Müller Heimo
Zatloukal Kurt
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
IMPORTANCE: Identifying new prognostic features in colon cancer has the potential to refine histopathologic review and inform patient care. Although prognostic artificial intelligence systems have recently demonstrated significant risk stratification for several cancer types, studies have not yet shown that the machine learning-derived features associated with these prognostic artificial intelligence systems are both interpretable and usable by pathologists. OBJECTIVE: To evaluate whether pathologist scoring of a histopathologic feature previously identified by machine learning is associated with survival among patients with colon cancer. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used deidentified, archived colorectal cancer cases from January 2013 to December 2015 from the University of Milano-Bicocca. All available histologic slides from 258 consecutive colon adenocarcinoma cases were reviewed from December 2021 to February 2022 by 2 pathologists, who conducted semiquantitative scoring for tumor adipose feature (TAF), which was previously identified via a prognostic deep learning model developed with an independent colorectal cancer cohort. MAIN OUTCOMES AND MEASURES: Prognostic value of TAF for overall survival and disease-specific survival as measured by univariable and multivariable regression analyses. Interpathologist agreement in TAF scoring was also evaluated. RESULTS: A total of 258 colon adenocarcinoma histopathologic cases from 258 patients (138 men [53%]; median age, 67 years [IQR, 65-81 years]) with stage II (n = 119) or stage III (n = 139) cancer were included. Tumor adipose feature was identified in 120 cases (widespread in 63 cases, multifocal in 31, and unifocal in 26). For overall survival analysis after adjustment for tumor stage, TAF was independently prognostic in 2 ways: TAF as a binary feature (presence vs absence: hazard ratio [HR] for presence of TAF, 1.55 [95% CI, 1.07-2.25]; P = .02) and TAF as a semiquantitative categorical feature (HR for widespread TAF, 1.87 [95% CI, 1.23-2.85]; P = .004). Interpathologist agreement for widespread TAF vs lower categories (absent, unifocal, or multifocal) was 90%, corresponding to a κ metric at this threshold of 0.69 (95% CI, 0.58-0.80). CONCLUSIONS AND RELEVANCE: In this prognostic study, pathologists were able to learn and reproducibly score for TAF, providing significant risk stratification on this independent data set. Although additional work is warranted to understand the biological significance of this feature and to establish broadly reproducible TAF scoring, this work represents the first validation to date of human expert learning from machine learning in pathology. Specifically, this validation demonstrates that a computationally identified histologic feature can represent a human-identifiable, prognostic feature with the potential for integration into pathology practice.
Find related publications in this database (using NLM MeSH Indexing)
Male - administration & dosage
Humans - administration & dosage
Aged - administration & dosage
Colonic Neoplasms - diagnosis
Pathologists - administration & dosage
Artificial Intelligence - administration & dosage
Adenocarcinoma - administration & dosage
Machine Learning - administration & dosage
Risk Assessment - administration & dosage

© Med Uni Graz Impressum